Component: (Network and Table)
Network
00400 - Statement - CONDENSED STATEMENTS OF CASH FLOWS
(http://www.corvuspharma.com/role/StatementCondensedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001626971 (http://www.sec.gov/CIK)
CONDENSED STATEMENTS OF CASH FLOWSPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-27 - 2014-12-31
CONDENSED STATEMENTS OF CASH FLOWS
 
 
 
Cash flows from operating activities
 
 
 
Net loss
(36,375,000) 
(31,335,000) 
(161,000) 
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation
594,000  
148,000  
 
Amortization/accretion related to marketable securities
648,000  
(41,000) 
 
Stock-based compensation
3,828,000  
428,000  
 
Change in fair value of convertible preferred stock liability
 
17,600,000  
 
Other
 
40,000  
 
Changes in operating assets and liabilities:
 
 
 
Prepaid and other current assets
290,000  
(1,265,000) 
(12,000) 
Other assets
(869,000) 
  
Accounts payable
518,000  
1,240,000  
57,000  
Accrued and other liabilities
2,814,000  
1,218,000  
17,000  
Other long-term liabilities
695,000  
639,000  
3,000  
Net cash used in operating activities
(27,857,000) 
 
(11,328,000) 
 
(96,000) 
 
Cash flows from investing activities
 
 
 
Purchases of marketable securities
(258,281,000) 
(104,385,000) 
 
Sales of marketable securities
4,199,000  
  
Maturities of marketable securities
213,725,000  
14,100,000  
 
Purchase of property and equipment
(2,199,000) 
(1,747,000) 
 
Net cash used in investing activities
(42,556,000) 
 
(92,032,000) 
 
 
 
Cash flows from financing activities
 
 
 
Proceeds from issuance of common stock in IPO, net of issuance costs
71,354,000  
 
2,000  
Proceeds from issuance of convertible preferred stock, net of issuance costs
 
95,569,000  
12,611,000  
Payment of offering costs
 
(729,000) 
 
Proceeds from exercise of common stock options
4,000  
108,000  
 
Net cash provided by financing activities
71,358,000  
 
94,948,000  
 
12,613,000  
 
Net increase in cash and cash equivalents
945,000  
 
(8,412,000) 
 
12,517,000  
 
Cash and cash equivalents at beginning of the period
4,105,000  
12,517,000  
 
Cash and cash equivalents at end of the period
5,050,000  
 
4,105,000  
 
12,517,000  
 
Supplemental disclosures of cash flow information
 
 
 
Convertible preferred stock issuance costs incurred but not paid
  
36,000  
Purchases of property and equipment incurred but not paid
84,000  
286,000  
 
Convertible preferred stock liability
  
2,600,000  
Deferred offering costs incurred but not paid
 
222,000